Hohl Benjamin 4

What Happened
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics (ELVN), sold 10,000 shares in an open-market transaction on March 6, 2026. The weighted-average sale price reported was $29.58 per share, resulting in total proceeds of approximately $295,839. This was a sale (disposition) rather than a purchase or grant.

Key Details

• Transaction date: March 6, 2026 (filed on March 10, 2026 — within the typical two-business-day Form 4 filing window).
• Reported price: weighted average $29.58; individual trades ranged from $29.43 to $29.7867 (see footnote F1).
• Shares sold: 10,000; total proceeds ≈ $295,839.
• Shares owned after transaction: not specified in the provided filing.
• Transaction type/code: Open-market sale (S).
• Footnotes: F1 notes multiple trades and availability of per-trade detail on request; F2 indicates some reported securities are restricted stock units (RSUs) that convert to shares subject to vesting conditions.

Context
Sales by executives can be routine (tax planning, diversification, liquidity) and do not by themselves indicate company performance. This filing documents a straightforward open-market sale; no exercise, gift, or 10b5-1 plan was stated in the provided notes.